CCO Treatment Updates
Answering the Questions: Initiating Antiretroviral Therapy
Answering the Questions: Initial Antiretroviral Therapy |
Module 1 of 2 |
  
- John A. Bartlett, MD
- Paul E. Sax, MD
- Benjamin Young, MD, PhD
|
|
|
John A. Bartlett, MD; Paul E. Sax, MD; and Benjamin Young, MD, PhD, in this roundtable answer the questions most pertinent to the initiation of antiretroviral therapy. Special considerations for unique patients and situations are discussed.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Explain guideline recommendations for timing of initiation of therapy
- Describe guideline-recommended initial regimens
- Recount tests and laboratory measurements that should be obtained before initiation of antiretroviral therapy
- Discuss situations in which therapy might be started earlier or later than recommended in the guidelines
- Describe several patients for whom individualization of therapy would be beneficial
|
Faculty Responses to Additional Questions on Initiating Antiretroviral Therapy |
Module 2 of 2 |
- John A. Bartlett, MD
- Paul E. Sax, MD
- Benjamin Young, MD, PhD
|
|
|
John A. Bartlett, MD; Paul E. Sax, MD; and Benjamin E. Young, MD, PhD, answer the most compelling additional questions on initiating antiretroviral therapy in HIV-infected antiretroviral-naive patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Explain risks and benefits of early therapy, that is, initiating antiretroviral therapy in patients with CD4+ cell counts ≥ 350 cells/mm3
- Describe strategies for building antiretroviral regimens for patients with baseline drug resistance
- Discuss the advantages and disadvantages of novel strategies (ie, other than 2 NRTIs plus a boosted PI or NNRTI) for first-line therapy
- Summarize special considerations when caring for pregnant HIV-infected patients and patients older than 50 years of age
- Cite evidence that helps guide the appropriate approach to patients with metabolic disorders, particularly hyperlipidemia and renal disease
- Recount data about the use of newer agents in first-line therapy
|
CCO Slideset
Answering the Questions: Initiating Antiretroviral Therapy
 |
|
Paul E. Sax, MD, reviews data that are relevant to frequently asked questions about initial antiretroviral therapy.
Format: Microsoft PowerPoint (.ppt) |
File size: 3.24 MB
| Date posted: 1/15/2009
|
Disclaimer:
The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|
|